Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has a high all-cause mortality rate and imposes a significant economic, epidemiological, and humanistic burden on the patients and healthcare system. Evidence from the published...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salman Hussain, Abanoub Riad, Ambrish Singh, Jitka Klugarová, Benny Antony, Hasanul Banna, Miloslav Klugar
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	coinfection COVID-19 epidemiology meta-analysis mucormycosis mycoses Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/b9d61247f58a4c9ca9fedacc70a33eb8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9d61247f58a4c9ca9fedacc70a33eb8
record_format	dspace
spelling	oai:doaj.org-article:b9d61247f58a4c9ca9fedacc70a33eb82021-11-25T18:06:32ZGlobal Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis10.3390/jof71109852309-608Xhttps://doaj.org/article/b9d61247f58a4c9ca9fedacc70a33eb82021-11-01T00:00:00Zhttps://www.mdpi.com/2309-608X/7/11/985https://doaj.org/toc/2309-608XMucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has a high all-cause mortality rate and imposes a significant economic, epidemiological, and humanistic burden on the patients and healthcare system. Evidence from the published epidemiological studies showed the varying prevalence of COVID-19-associated mucormycosis (CAM). This study aims to compute the pooled prevalence of CAM and other associated clinical outcomes. MEDLINE, Embase, Cochrane COVID-19 Study Register, and WHO COVID-19 databases were scanned to retrieve the relevant articles until August 2021. All studies reporting the prevalence of mucormycosis among COVID-19 patients were eligible for inclusion. Two investigators independently screened the articles against the selection criteria, extracted the data, and performed the quality assessment using the JBI tool. The pooled prevalence of CAM was the primary outcome, and the pooled prevalence of diabetes, steroid exposure, and the mortality rate were the secondary outcomes of interest. Comprehensive Meta-Analysis software version 2 was used for performing the meta-analysis. This meta-analysis comprised six studies with a pooled sample size of 52,916 COVID-19 patients with a mean age of 62.12 ± 9.69 years. The mean duration of mucormycosis onset was 14.59 ± 6.88 days after the COVID-19 diagnosis. The pooled prevalence of CAM (seven cases per 1000 patients) was 50 times higher than the highest recorded background of mucormycosis (0.14 cases per 1000 patients). A high mortality rate was found among CAM patients with a pooled prevalence rate of 29.6% (95% CI: 17.2–45.9%). Optimal glycemic control and the judicious use of steroids should be the approach for tackling rising CAM cases.Salman HussainAbanoub RiadAmbrish SinghJitka KlugarováBenny AntonyHasanul BannaMiloslav KlugarMDPI AGarticlecoinfectionCOVID-19epidemiologymeta-analysismucormycosismycosesBiology (General)QH301-705.5ENJournal of Fungi, Vol 7, Iss 985, p 985 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	coinfection COVID-19 epidemiology meta-analysis mucormycosis mycoses Biology (General) QH301-705.5
spellingShingle	coinfection COVID-19 epidemiology meta-analysis mucormycosis mycoses Biology (General) QH301-705.5 Salman Hussain Abanoub Riad Ambrish Singh Jitka Klugarová Benny Antony Hasanul Banna Miloslav Klugar Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis
description	Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has a high all-cause mortality rate and imposes a significant economic, epidemiological, and humanistic burden on the patients and healthcare system. Evidence from the published epidemiological studies showed the varying prevalence of COVID-19-associated mucormycosis (CAM). This study aims to compute the pooled prevalence of CAM and other associated clinical outcomes. MEDLINE, Embase, Cochrane COVID-19 Study Register, and WHO COVID-19 databases were scanned to retrieve the relevant articles until August 2021. All studies reporting the prevalence of mucormycosis among COVID-19 patients were eligible for inclusion. Two investigators independently screened the articles against the selection criteria, extracted the data, and performed the quality assessment using the JBI tool. The pooled prevalence of CAM was the primary outcome, and the pooled prevalence of diabetes, steroid exposure, and the mortality rate were the secondary outcomes of interest. Comprehensive Meta-Analysis software version 2 was used for performing the meta-analysis. This meta-analysis comprised six studies with a pooled sample size of 52,916 COVID-19 patients with a mean age of 62.12 ± 9.69 years. The mean duration of mucormycosis onset was 14.59 ± 6.88 days after the COVID-19 diagnosis. The pooled prevalence of CAM (seven cases per 1000 patients) was 50 times higher than the highest recorded background of mucormycosis (0.14 cases per 1000 patients). A high mortality rate was found among CAM patients with a pooled prevalence rate of 29.6% (95% CI: 17.2–45.9%). Optimal glycemic control and the judicious use of steroids should be the approach for tackling rising CAM cases.
format	article
author	Salman Hussain Abanoub Riad Ambrish Singh Jitka Klugarová Benny Antony Hasanul Banna Miloslav Klugar
author_facet	Salman Hussain Abanoub Riad Ambrish Singh Jitka Klugarová Benny Antony Hasanul Banna Miloslav Klugar
author_sort	Salman Hussain
title	Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis
title_short	Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis
title_full	Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis
title_fullStr	Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis
title_full_unstemmed	Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis
title_sort	global prevalence of covid-19-associated mucormycosis (cam): living systematic review and meta-analysis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b9d61247f58a4c9ca9fedacc70a33eb8
work_keys_str_mv	AT salmanhussain globalprevalenceofcovid19associatedmucormycosiscamlivingsystematicreviewandmetaanalysis AT abanoubriad globalprevalenceofcovid19associatedmucormycosiscamlivingsystematicreviewandmetaanalysis AT ambrishsingh globalprevalenceofcovid19associatedmucormycosiscamlivingsystematicreviewandmetaanalysis AT jitkaklugarova globalprevalenceofcovid19associatedmucormycosiscamlivingsystematicreviewandmetaanalysis AT bennyantony globalprevalenceofcovid19associatedmucormycosiscamlivingsystematicreviewandmetaanalysis AT hasanulbanna globalprevalenceofcovid19associatedmucormycosiscamlivingsystematicreviewandmetaanalysis AT miloslavklugar globalprevalenceofcovid19associatedmucormycosiscamlivingsystematicreviewandmetaanalysis
_version_	1718411639282204672

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

Ejemplares similares